Generated by All in One SEO v4.8.8, this is an llms.txt file, used by LLMs to index the site.

# ReCode Therapeutics

Powering the future of genetic medicines through superior delivery.

## Sitemaps

- [XML Sitemap](https://recodetx.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [ReCode Therapeutics Announces New Funding from the Cystic Fibrosis Foundation, Collaboration with a Leading Gene Editing Company and Leadership Transition](https://recodetx.com/recode-therapeutics-announces-new-funding-from-the-cystic-fibrosis-foundation-collaboration-with-a-leading-gene-editing-company-and-leadership-transition/) - ReCode Therapeutics Announces New Funding from the Cystic Fibrosis Foundation, Collaboration with a Leading Gene Editing Company and Leadership Transition
- [ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients](https://recodetx.com/recode-therapeutics-achieves-a-first-proof-of-activity-in-primary-ciliary-dyskinesia-patients/) - ReCode Therapeutics Achieves a First: Proof of Activity in Primary Ciliary Dyskinesia Patients
- [ReCode Therapeutics Announces Additional Funding from the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis](https://recodetx.com/recode-therapeutics-announces-additional-funding-from-the-cystic-fibrosis-foundation-to-accelerate-development-of-novel-gene-correction-therapeutics-to-treat-cystic-fibrosis/) - The Cystic Fibrosis Foundation has agreed to invest up to $15 million in new funding to support the company’s gene correction development program with Intellia Therapeutics for the treatment of cystic fibrosis
- [ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis](https://recodetx.com/recode-therapeutics-initiates-enrollment-of-phase-2-clinical-trial-of-rct2100-in-combination-with-ivacaftor-for-the-treatment-of-cystic-fibrosis/) - RCT-2100 co-administered with ivacaftor will assess the safety and tolerability of inhaled CFTR mRNA therapy over 6 weeks in participants with CF. U.S. sites now enrolling, with U.K. and EU sites expected to begin enrollment in Q1 2026
- [ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update](https://recodetx.com/recode-therapeutics-announces-over-29-million-in-additional-financing-to-advance-genetic-medicines-pipeline-and-provides-corporate-update/) - Cystic Fibrosis Foundation provides $3 million in new funding to accelerate development of inhaled mRNA therapy for cystic fibrosis. Research collaboration with Praxis Precision Medicines to develop LNP formulations for ASO delivery.
- [Inhaled DNAI1 mRNA therapy for treatment of primary ciliary dyskinesia](https://www.pnas.org/doi/full/10.1073/pnas.2421915122#new_tab) - PNAS
- [In vivo editing of lung stem cells for durable gene correction in mice](https://www.science.org/doi/10.1126/science.adk9428#new_tab) - Science
- [RCT2100 rescue of cystic fibrosis (CF) transmembrane conductance regulator function in CF human bronchial epithelial cells and mucociliary clearance in CF ferrets](https://www.researchgate.net/publication/383758519_260_RCT2100_rescue_of_cystic_fibrosis_CF_transmembrane_conductance_regulator_function_in_CF_human_bronchial_epithelial_cells_and_mucociliary_clearance_in_CF_ferrets#new_tab) - Journal of Cystic Fibrosis
- [ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis](https://recodetx.com/recode-therapeutics-receives-u-s-fda-orphan-drug-designation-for-rct2100-for-the-treatment-of-cystic-fibrosis/) - Menlo Park, Calif. – March 25, 2025 – ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RCT2100, a novel, investigational mRNA therapy being developed to treat cystic
- [ReCode Announces Two Key Additions to Scientific Advisory Board](https://recodetx.com/recode-announces-two-key-additions-to-scientific-advisory-board/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today presented preclinical data from its mRNA-based cystic fibrosis (CF) program at the North American Cystic Fibrosis Conference (NACFC), taking place September 26-28, 2024, in Boston, Massachusetts.
- [ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis](https://recodetx.com/recode-therapeutics-doses-first-patient-in-phase-1b-clinical-study-of-rct2100-for-the-treatment-of-cystic-fibrosis/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the first patient has been dosed in a Phase 1b study evaluating RCT2100, an investigational inhaled mRNA therapy for people with cystic fibrosis (CF).
- [ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston](https://recodetx.com/recode-therapeutics-presents-preclinical-data-from-its-cystic-fibrosis-program-at-the-2024-north-american-cystic-fibrosis-conference-nacfc-in-boston/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today presented preclinical data from its mRNA-based cystic fibrosis (CF) program at the North American Cystic Fibrosis Conference (NACFC), taking place September 26-28, 2024, in Boston, Massachusetts.
- [ReCode Therapeutics to Participate in Upcoming Investor Conferences](https://recodetx.com/recode-therapeutics-to-participate-in-upcoming-investor-conferences-2/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences.
- [ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia](https://recodetx.com/recode-therapeutics-receives-u-s-fda-orphan-drug-designation-for-rct1100-for-the-treatment-of-primary-ciliary-dyskinesia/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences.
- [Research Associate II, Bioanalytical Development (Contract)](https://boards.greenhouse.io/recodetherapeutics/jobs/4432120007?gh_jid=4432120007#new_tab) - Menlo Park, CA
- [New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction](https://recodetx.com/new-article-published-in-science-highlights-the-potential-of-recode-therapeutics-systemic-lung-delivery-and-cftr-gene-correction/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences.
- [Scientist II, Chemistry](https://boards.greenhouse.io/recodetherapeutics/jobs/4389308007?gh_jid=4389308007#new_tab) - Menlo Park, CA
- [ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of its Board of Directors](https://recodetx.com/recode-therapeutics-announces-appointment-of-dean-j-mitchell-as-chairman-of-its-board-of-directors/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences.
- [ReCode Therapeutics to Participate in May Conferences](https://recodetx.com/recode-therapeutics-to-participate-in-may-conferences/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences.
- [Senior/Executive Director, Translational Sciences & Nonclinical Operations](https://boards.greenhouse.io/recodetherapeutics/jobs/4267897007?gh_jid=4267897007#new_tab) - Menlo Park, CA
- [ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis](https://recodetx.com/recode-therapeutics-announces-first-participants-dosed-in-a-phase-1-healthy-volunteer-clinical-study-of-inhaled-mrna-based-genetic-medicine-rct2100-for-the-treatment-of-cystic-fibrosis/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announcedthat the first cohort of healthy volunteer participants have been dosed in a Phase 1 clinical study of RCT2100, an inhaled mRNA-based investigational therapy for cystic fibrosis (CF) that focuses specifically on the 10-13% of patients with nonsense mutations that do not respond to or experience side effects with, approved CFTR modulators.
- [ReCode Therapeutics to Participate in February Conferences](https://recodetx.com/recode-therapeutics-to-participate-in-february-conferences/) - ReCode today announced that company management will participate in the upcoming February conferences... ReCode Therapeutics today announced that company management will participate in the upcoming February conferences...
- [Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis](https://recodetx.com/intellia-therapeutics-and-recode-therapeutics-announce-strategic-collaboration-to-develop-novel-gene-editing-therapies-for-cystic-fibrosis/) - Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP)to extend the reach of gene editing to disease-causing targets in the lung.
- [ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia](https://recodetx.com/recode-therapeutics-doses-first-patient-in-phase-1-clinical-study-of-novel-mrna-based-therapy-for-the-treatment-of-primary-ciliary-dyskinesia/) - – Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations in the DNAI1 gene – – RCT1100 is the first clinical evaluation of an inhaled mRNA-based therapy designed to restore ciliary function in people with PCD – Menlo Park, Calif. –
- [On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles](https://doi.org/10.1073/pnas.2109256118#new_tab) - PNAS
- [The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles](https://doi.org/10.1016/j.jconrel.2023.07.058#new_tab) - Journal of Controlled Release
- [Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models](https://www.nature.com/articles/s41467-023-42948-2#new_tab) - Nature Communications
- [Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery](https://www.nature.com/articles/s41596-022-00755-x#new_tab) - Nature Protocols
- [Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing](https://www.nature.com/articles/s41565-020-0669-6#new_tab) - Nature Nanotechnology
- [ReCode Therapeutics to Participate in November Conferences](https://recodetx.com/recode-therapeutics-to-participate-in-november-conferences/) - Menlo Park, Calif. – Nov. 10, 2023 – ReCode Therapeutics, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming November conferences: Stifel 2023 Healthcare Conference Format: Company PresentationDate: November 14, 2023Time: 4:10 p.m. ETLocation: New York
- [Unshackling genetic medicines by enabling delivery beyond the liver](https://www.nature.com/articles/d43747-023-00052-w#new_tab) - Nature Biopharma Dealmakers
- [Aerosolized Therapy Restores CFTR in Patient-derived Cells](https://cysticfibrosisnewstoday.com/news/aerosolized-mrna-based-therapy-restores-cftr-function-cells/#new_tab) - Cystic Fibrosis News Today
- [ReCode Therapeutics Announces Closing of Extension to Series B Financing](https://recodetx.com/recode-therapeutics-announces-closing-of-extension-to-series-b-financing/) - – Total of $260 million in Series B funding includes an additional $50 million from existing and new investors, Bioluminescence Ventures and Solasta Ventures – Menlo Park, Calif. – Sept. 19, 2023 – ReCode Therapeutics, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today
- [ReCode Therapeutics to Present at September Investor Conferences](https://recodetx.com/recode-therapeutics-to-present-at-september-investor-conferences/) - Menlo Park, Calif. – September 7, 2023 – ReCode Therapeutics, a clinical-stage company powering the next wave of genetic medicines, today announced that Company management will participate in the following upcoming investor conferences in September 2023: Morgan Stanley Global Healthcare Conference:Format: Company PresentationDate: September 12, 2023Time: 12:55 p.m. ETPresenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of
- [Recode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs](https://recodetx.com/recode-therapeutics-appoints-erica-jefferson-as-senior-vice-president-of-corporate-affairs/) - ReCode Therapeutics strengthens leadership team with appointment of Erica Jefferson as Senior Vice President of Corporate Affairs.
- [ReCode Therapeutics to Present at Jefferies Healthcare Conference](https://recodetx.com/recode-therapeutics-to-present-at-jefferies-healthcare-conference/) - Menlo Park, Calif. – June 2, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Angèle Maki, Ph.D., Senior Vice President, Business Development of ReCode Therapeutics, will present a company overview at 8:30 a.m. ET on Friday, June 9,
- [ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer](https://recodetx.com/recode-therapeutics-appoints-shehnaaz-suliman-m-d-mba-m-phil-as-chief-executive-officer/) - Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform Menlo Park, Calif. And Dallas, Texas – January 10, 2022 – ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic
- [ReCode Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference](https://recodetx.com/recode-therapeutics-to-present-at-40th-annual-j-p-morgan-healthcare-conference/) - Menlo Park, Calif. and Dallas, Texas – January 10, 2022 – ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Company leadership will present virtually at the 40th Annual J.P. Morgan Healthcare Conference. Presentation details: Date: Thursday, January 13, 2022
- [Seven technologies to watch in 2022](https://www.nature.com/articles/d41586-022-00163-x#new_tab) - Nature
- [ReCode Therapeutics to Present at Oppenheimer 32nd Annual Healthcare Conference](https://recodetx.com/recode-therapeutics-to-present-at-oppenheimer-32nd-annual-healthcare-conference/) - Menlo Park, Calif. and Dallas, Texas – March 9, 2022 – ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil, chief executive officer of ReCode Therapeutics will present a corporate overview at the upcoming Oppenheimer 32nd Annual
- [ReCode Therapeutics Corporate Presentation](https://wsw.com/webcast/oppenheimer20/register.aspx?conf=oppenheimer20&page=reco&url=https://wsw.com/webcast/oppenheimer20/reco/2761038#new_tab) - Oppenheimer 32nd Annual Healthcare Conference
- [ReCode Therapeutics to Present Preclinical Data Using Proprietary SORT LNP Delivery Platform from its mRNA-based Therapeutic Programs at the ATS 2022 International Conference in San Francisco](https://recodetx.com/recode-therapeutics-to-present-preclinical-data-using-proprietary-sort-lnp-delivery-platform-from-its-mrna-based-therapeutic-programs-at-the-ats-2022-international-conference-in-san-francisco/) - Menlo Park, Calif. and Dallas, Texas – May 3, 2022 – ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its selective organ targeting (SORT) lipid nanoparticles (LNP) delivery platform, today announced that it will present preclinical data from its mRNA-based therapeutic programs in cystic fibrosis and primary ciliary dyskinesia at the American Thoracic
- [ReCode Therapeutics to Present at 2022 RBC Capital Markets Global Healthcare Conference](https://recodetx.com/recode-therapeutics-to-present-at-2022-rbc-capital-markets-global-healthcare-conference/) - Menlo Park, Calif. and Dallas, Texas – May 10, 2022 – ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) lipid nanoparticle (LNP) delivery platform, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat on Tuesday, May
- [Rescue of Ciliary Function in Cell-based Primary Ciliary Dyskinesia Models using Nebulized, LNP-formulated mRNA](/wp-content/uploads/2022/10/ATS-Poster-Rumpa_ReCode-Therapeutics_FINAL_EH.pdf#new_tab) - American Thoracic Society (ATS) 2022 International Conference
- [Optimization of DNAI1 mRNA Constructs to Treat Primary Ciliary Dyskinesia](/wp-content/uploads/2022/10/ATS-Poster-Mirko-15Apr2022.pdf#new_tab) - American Thoracic Society (ATS) 2022 International Conference
- [An mRNA-Based Therapy to Treat Primary Ciliary Dyskinesia: Aerosol Delivery, Biodistribution and Tolerability](/wp-content/uploads/2022/10/2022-05-10-ATS-2022-Poster-Dave-FINAL_EH.pdf#new_tab) - American Thoracic Society (ATS) 2022 International Conference
- [ReCode Therapeutics to Participate in Upcoming July Investor Conferences](https://recodetx.com/recode-therapeutics-to-participate-in-upcoming-july-investor-conferences/) - Menlo Park, Calif. and Dallas, Texas – July 6, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Company leadership will participate in two upcoming investor conferences in July: William Blair Biotech Focus Conference (New York, NY)Format: Panel PresentationDate:
- [ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference](https://recodetx.com/recode-therapeutics-presents-preclinical-data-from-inhaled-mrna-therapeutic-program-in-primary-ciliary-dyskinesia-pcd-in-three-posters-at-the-ats-2022-international-conference/) - ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) formulation of DNAI1 mRNA was successfully and directly delivered to lungs as an inhaled aerosol with no significant exposure to other tissues SORT LNP-formulated DNAI1 mRNA demonstrates long-lasting functional recovery and is well-tolerated with rapid clearance of LNP lipids allowing repeat administration ReCode to present new preclinical
- [ReCode breaks the mold with $120M financing, bringing clutch of Big Pharmas along for ride](https://www.fiercebiotech.com/biotech/recode-therapeutics-breaks-funding-algorithm-200m-oversubscribed-series-b-amid-push-get#new_tab) - Fierce Biotech
- [Pfizer, Sanofi-backed LNP outfit goes back to the well and draws $120M for its trek to the clinic](https://endpts.com/pfizer-sanofi-backed-lnp-outfit-goes-back-to-the-well-and-draws-120m-for-its-trek-to-the-clinic/#new_tab) - Endpoints News
- [ReCode Therapeutics Raises $200M in Series B](https://www.insideprecisionmedicine.com/topics/molecular-dx-topic/rna/mrna/recode-therapeutics-raises-200m-in-series-b/#:~:text=Gene correction and mRNA company,with participation from Amgen Ventures.#new_tab) - Inside Precision Medicine
- [Peninsula company raises $120M to build new vehicles for mRNA drugs, other therapies](https://www.bizjournals.com/sanfrancisco/news/2022/06/29/cancer-mrna-gene-therapy-cf-recode-therapeutics.html#new_tab) - San Francisco Business Times
- [SORTing It Out: ReCode Expands Beyond Respiratory Disorders](https://www.genengnews.com/topics/drug-discovery/drug-delivery/sorting-it-out-recode-expands-beyond-respiratory-disorders/#new_tab) - Genetic Engineering & Biotechnology News
- [ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines](https://scrip.pharmaintelligence.informa.com/SC146637/ReCode-Raises-Another-$120m-To-Broaden-LNP-Delivery-Of-Genetic-Medicines#new_tab) - Scrip Pharma Intelligence
- [ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M](https://recodetx.com/recode-therapeutics-to-expand-next-generation-delivery-platform-and-diversify-genetic-medicines-pipeline-with-oversubscribed-series-b-financing-totaling-200m/) - – Series B extension co-led by AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer, with participation from Amgen Ventures. Adds to Existing Investors, including Pfizer Ventures, EcoR1 Capital and Sanofi Ventures. – – Proceeds to expand and diversify platform and pipeline to include mRNA and gene correction therapeutics for central nervous system,
- [ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference](https://recodetx.com/recode-therapeutics-presents-new-preclinical-data-from-mrna-based-program-for-cystic-fibrosis-at-the-ats-2022-international-conference/) - Study confirms the ability of ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to deliver optimized, functional CFTR mRNA as an aerosol directly to specific cell targets Results show consistent rescue of CFTR function across multiple cystic fibrosis patient genotypes, including genotypes that do not respond to approved CFTR modulator treatments Menlo Park, Calif.
- [Functional Rescue of CFTR by Aerosolized Delivery of Optimized CFTR mRNA Using ReCode LNPs in Primary Human Bronchial Epithelial Cells Derived From Patients With Cystic Fibrosis](/wp-content/uploads/2022/10/ATS-Poster-Daniella-15Apr2022_FINAL-Oct2022.pdf#new_tab) - American Thoracic Society (ATS) 2022 International Conference
- [ReCode Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference](https://recodetx.com/recode-therapeutics-to-present-at-morgan-stanley-20th-annual-global-healthcare-conference/) - MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)--ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a corporate overview at 8:00 a.m. ET on Tuesday, September 13th at the upcoming
- [Fierce Biotech Names ReCode Therapeutics as One of its “Fierce 15” Biotech Companies of 2022](https://recodetx.com/fierce-biotech-names-recode-therapeutics-as-one-of-its-fierce-15-biotech-companies-of-2022/) - Fierce Biotech has named ReCode Therapeutics as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
- [See the 13-slide pitch deck a biotech used to raise $120M and write the next chapter in mRNA medicines](https://www.businessinsider.com/recode-therapeutics-13-slide-pitch-deck-series-b-raise-2022-6#new_tab) - Business Insider
- [ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit](https://recodetx.com/recode-therapeutics-to-present-at-jefferies-cell-and-genetic-medicine-summit/) - Menlo Park, Calif. and Dallas, Texas – September 22, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D, President and Chief Scientific Officer of ReCode Therapeutics, will present a company overview at 8:00 a.m. ET on
- [ReCode Therapeutics to Participate in Upcoming October Investor Conferences](https://recodetx.com/recode-therapeutics-to-participate-in-upcoming-october-investor-conferences/) - Menlo Park, Calif. and Dallas, Texas – September 26, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in October: Chardan’s 6th Annual Genetic Medicines ConferenceFormat: Company PresentationDate: Monday, October
- [Fierce Biotech's 2022 Fierce15](https://www.fiercebiotech.com/special-reports/fierce-biotechs-2022-fierce-15#new_tab) - Fierce Biotech
- [ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia](https://recodetx.com/recode-therapeutics-announces-first-participants-dosed-in-a-phase-1-healthy-volunteer-clinical-trial-of-novel-disease-modifying-genetic-medicine-rct1100-for-the-treatment-of-primary-ciliary-dyskinesi/) - Phase 1 trial to evaluate safety and tolerability of a single ascending dose of RCT1100, an inhaled mRNA-based genetic medicine First clinical-stage candidate from ReCode’s proprietary SORT LNP delivery platform designed to restore ciliary function in the lungs of people with PCD caused by pathogenic mutations in the DNAI1 gene; IND submission planned for 2H23
- [ReCode Therapeutics Appoints Trisha Millican to Board of Directors](https://recodetx.com/recode-therapeutics-appoints-trisha-millican-to-board-of-directors/) - Veteran life sciences industry financial executive appointed as independent member of the Board of Directors Menlo Park, Calif. and Dallas, Texas – December 1, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of Patricia “Trisha” Millican to
- [Ep124: Shehnaaz Suliman on Delivery of Genetic Medicines](https://soundcloud.com/longrunpodcast/ep124-shehnaaz-suliman-on-delivery-of-genetic-medicines?utm_source=mobi&utm_campaign=social_sharing#new_tab) - The Long Run with Luke Timmerman
- [ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference](https://recodetx.com/recode-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference/) - Menlo Park, Calif. – January 3, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a company overview at 9:00 a.m. PT on Tuesday, January 10,
- [ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform](https://recodetx.com/recode-therapeutics-announces-strategic-collaboration-with-askbio-to-explore-single-vector-gene-editing-platform/) - Collaboration will combine ReCode’s unique delivery technology with AskBio’s gene editing and DNA cargoes to develop novel gene correction therapies for the liver and lung Menlo Park, Calif. – January 9, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today
- [Biotech backed by who’s who of Big Pharma nabs AskBio deal](https://endpts.com/fda-accepts-one-delays-another-data-deals-and-dollars-for-slate-of-biotechs/#new_tab) - Endpoints News
- [ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy](https://recodetx.com/recode-therapeutics-announces-strategic-investment-from-the-cystic-fibrosis-foundation-to-accelerate-development-of-novel-mrna-therapy/) - Cystic Fibrosis Foundation will invest up to $15 million to help advance the development of ReCode’s CFTR mRNA therapy for cystic fibrosis Menlo Park, Calif.– January 10, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that it will receive
- ['Beyond Vaccines': Biotech Is Booming in the Bay Area Despite a Cooling Economy](https://www.kqed.org/news/11933882/beyond-vaccines-biotech-is-booming-in-the-bay-area-despite-a-cooling-economy#new_tab) - KQED
- [ReCode Therapeutics Company Overview](https://recodetx.com/wp-content/uploads/2023/02/2023-ReCode-JPM-presentation.pdf#new_tab) - 41st Annual J.P. Morgan Healthcare Conference
- [Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory](https://recodetx.com/recode-therapeutics-expands-leadership-team-with-appointment-of-april-loui-as-senior-vice-president-of-quality-and-cmc-regulatory/) - Distinguished biotech industry veteran brings decades of experience to lead the scale-up of manufacturing capabilities for ReCode’s pipeline of first-in-class precision genetic medicines Menlo Park, Calif. – February 1, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of
- [Nebulized LNP-formulated DNAI1 mRNA Therapy to Restore Mucociliary Clearance for the Treatment of Primary Ciliary Dyskinesia](https://recodetx.com/wp-content/uploads/2023/02/Hennig_GRC-2023.pdf#new_tab) - 2023 Cilia, Mucus and Mucociliary Interactions GRC
- [Aerosolized lipid nanoparticle/mRNA therapy to treat patients with Cystic Fibrosis](https://recodetx.com/wp-content/uploads/2023/02/Ishimaru_GRC-2023.pdf#new_tab) - 2023 Cilia, Mucus and Mucociliary Interactions GRC
- [ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines](https://recodetx.com/recode-therapeutics-to-present-at-bmo-biopharma-spotlight-series-novel-technologies-for-the-delivery-of-genetic-medicines/) - Menlo Park, Calif. – March 21, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at
- [ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days](https://recodetx.com/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days/) - Menlo Park, Calif. – March 27, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat at 9:35 a.m. ET on Monday, April
- [Recode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development](https://recodetx.com/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development/) - Renowned physician-scientist brings deep expertise in clinical development and inhaled drug delivery to ReCode as lead programs for primary ciliary dyskinesia and cystic fibrosis enter clinical trials
- [Best Places to Work in the Bay Area 2023](https://www.bizjournals.com/sanfrancisco/news/2023/05/05/best-workplaces-bay-area.html#new_tab) - San Francisco Business Times
- [ReCode Therapeutics Establishes Scientific Advisory Board](https://recodetx.com/recode-therapeutics-establishes-scientific-advisory-board/) - Members include distinguished academic and industry leaders with expertise in genetic medicine, delivery technology and drug development Menlo Park, Calif. and Dallas, Texas – November 14, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the formation of the company's
- [ReCode Therapeutics to Participate in Upcoming November Investor Conferences](https://recodetx.com/recode-therapeutics-to-participate-in-upcoming-november-investor-conferences-2/) - Menlo Park, Calif. and Dallas, Texas – November 2, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in November: Credit Suisse 31st Annual Healthcare ConferenceFormat: Company PresentationDate: Wednesday, November
- [Rescue of Ciliary Function in Primary Ciliary Dyskinesia using Nebulized LNP-formulated DNAI1 mRNA](https://recodetx.com/wp-content/uploads/2023/01/221004-ReCode-Cilia.pdf#new_tab) - 5th European Cilia Conference
- [ReCode Therapeutics to Present at Upcoming Investor Conferences in 2022](https://recodetx.com/recode-therapeutics-to-present-at-upcoming-investor-conferences-in-2022/) - Menlo Park, Calif. and Dallas, Texas – November 22, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in November: Piper Sandler 34th Annual Healthcare ConferenceFormat: Company PresentationDate: Tuesday, November

## Pages

- [Powering the future of genetic medicines through superior delivery](https://recodetx.com/) - ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized mRNA and gene correction with redosing capability.
- [Cystic Fibrosis](https://recodetx.com/cf/) - Tackling Cystic Fibrosis from Multiple Angles CF is a progressive, fatal genetic disease which, if left untreated, can cause persistent lung infections and respiratory failure. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and impacts approximately 105,000 people worldwide. Despite advancements in CFTR modulator treatments, approximately 10% of the
- [Clinical Studies](https://recodetx.com/clinical-studies/) - Clinical Studies Cystic Fibrosis (CF) CF-Clinical-Studies.com: A Clinical Study for People with CF Who Have Specific Mutations in the CFTR Gene, Which Are the Cause of CF ClinicalTrials.gov: A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants with CF ClinicalTrials.gov: A Phase 2 Study Evaluating Safety and Tolerability
- [Primary Ciliary Dyskinesia](https://recodetx.com/pcd/) - New Treatment Possibilities in Primary Ciliary Dyskinesia PCD is a rare genetic disorder that leads to chronic respiratory infections. PCD affects the cilia, the tiny hair-like structures on the surface of cells that line the upper and lower airways. This leads to mucus and debris building up in the respiratory tract, sinuses, and ears. Consequently,
- [Opt-out preferences](https://recodetx.com/opt-out-preferences/)
- [Pipeline](https://recodetx.com/pipeline/) - Our indications span across primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and liver, spleen and central nervous system (CNS) diseases.
- [Leadership](https://recodetx.com/leadership/) - Leadership We’ve assembled an experienced team with substantial genetic medicines, orphan drug development, and technology development expertise from small and large biopharma companies. Shehnaaz Suliman, M.D., M.B.A., M.Phil. President & Chief Executive Officer John G. Matthews, MBBS, MRCP, Ph.D. Chief Medical Officer Jessica Couch, Ph.D. Chief Scientific Officer Vladimir Kharitonov, Ph.D. Senior Vice President, CMC
- [Partnering](https://recodetx.com/partnering/) - Powering the Next Wave of Precision Genetic Medicines — Together We believe in winning together and importantly, winning in our shared mission to help more patients in need. Our goal is to maximize the potential of our SORT LNP delivery technology even beyond those rare diseases in our pipeline so that more patients may realize
- [Careers & Culture](https://recodetx.com/careers-culture/) - ReCode Your Future Do you have a desire to leave a lasting imprint on the future of medicine? ReCode has the potential to be just as game-changing for your career as our technology is for the future of genetic medicine. Follow us on Linkedin Instagram Our Values Power the Next Wave of Genetic Medicine We
- [Science](https://recodetx.com/science/) - Our selective organ targeting (SORT) lipid nanoparticles (LNPs) are engineered with a distinct fifth lipid to help the body “sort” and direct the LNPs to targeted organs with the ability to bypass the liver.
- [Our Purpose](https://recodetx.com/about/) - The Why Behind Our Work We imagine a world where people living with genetic diseases can fully benefit from the promise of genetic medicines. Our novel mRNA and gene correction therapeutics have the potential to make this a reality. Our Story Begins with Unconventional Thinking For decades, LNP delivery was confined to the liver, limiting
- [Media Library](https://recodetx.com/media-library/) - Media Library ReCode Therapeutics We imagine a world where people living with genetic diseases can fully benefit from the promise of genetic medicines. Our novel mRNA and gene correction therapeutics have the potential to make this a reality. Logo Photography SHEHNAAZ SULIMAN, M.D., M.B.A., M.Phil.Chief Executive Officer SHEHNAAZ SULIMAN, M.D., M.B.A., M.Phil.Chief Executive Officer SHEHNAAZ SULIMAN,
- [News](https://recodetx.com/news/) - ReCode in the News Press Releases March 25, 2025 ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis Menlo Park, Calif. – March 25, 2025 – ReCode Therapeutics, a clinical-stage genetic medicines company using November 18, 2024 ReCode Therapeutics Announces Additional Funding from the Cystic Fibrosis Foundation to Accelerate
- [Patients](https://recodetx.com/patients/) - For people living with rare and common genetic diseases Cystic Fibrosis (CF) ReCode is developing an inhaled mRNA therapy for the 10% of people with CF who have mutations in the CFTR gene and do not respond to currently approved CFTR modulators. ReCode is also advancing a gene correction therapy designed to repair specific mutations
- [Events](https://recodetx.com/events/) - Events
- [Cookie Policy](https://recodetx.com/cookie-policy/) - Last updated: October 2023 This Policy describes how and why ReCode Therapeutics (“ReCode”, “we”, “us” or “our”) uses cookies on our website: https://recodetx.com/ (the “Website”). What are cookies? A cookie is a small piece of data (text file) that a website or app – when visited by a user – asks your browser to
- [Terms & Conditions](https://recodetx.com/terms-conditions/) - Read ReCode Therapeutics' terms of use.
- [Privacy Policy](https://recodetx.com/privacy-policy/) - Read ReCode Therapeutics' privacy policy.

## My Templates

- [Site Footer](https://recodetx.com/?elementor_library=site-footer) - Menlo Park 1140 O’Brien Drive Menlo Park, CA 94025 Linkedin Instagram Connect Partnering partnering@recodetx.comInvestor Relations IR@recodetx.comMedia Relations media@recodetx.com Company About Science Pipeline Partner × About Science Pipeline Partner People Patients Team Careers × Patients Team Careers © ReCode Therapeutics 2026. All Rights Reserved. Site by The Grace Communication Group. Terms & Conditions Privacy Policy
- [Heather Clark, M.S.](https://recodetx.com/?elementor_library=heather-clark-m-s) - Heather L. Clark, M.S. Senior Vice President, Cystic Fibrosis Franchise & Head of Program Management Office Ms. Clark is senior vice president and head of the cystic fibrosis (CF) franchise as well as head of the program management office at ReCode Therapeutics. She joined the company in 2022 and leadsstrategy for CF, including oversight of
- [Events carousel](https://recodetx.com/?elementor_library=events-carousel) - Where to find ReCode this month: VIEW ALL EVENTS
- [Jessica Couch](https://recodetx.com/?elementor_library=jessica-couch) - Jessica Couch, Ph.D. Chief Scientific Officer Dr. Couch has nearly 20 years of translational science, project team leadership, and portfolio strategy experience with a proven track record of bringing discoveries from the laboratory to patients. Prior to joining ReCode, Dr. Couch spent 14 years at Genentech, Inc., where she grew in positions of increasing leadership.
- [Testimonial - 2 column](https://recodetx.com/?elementor_library=testimonial-2-column) - “Our inhaled CFTR mRNA therapy is optimized to reach the correct cells in the lungs and instruct them to make a functional version of the CFTR protein. This would represent an exciting step in developing a successful therapy for all CF patients.” “The promise of gene correction therapies is that we’ll be able to go
- [Program Section](https://recodetx.com/?elementor_library=program-section) - Programs Cystic Fibrosis The company’s lead mRNA candidate for cystic fibrosis (CF) is in Phase 1 clinical development. ReCode is also advancing a gene correction therapeutic aimed at repairing disease-causing CFTR mutations directly in the lungs. Primary Ciliary Dyskinesia ReCode’s lead program for primary ciliary dyskinesia (PCD) is in Phase 1 clinical development Future Indications
- [Light Background](https://recodetx.com/?elementor_library=light-background-2) - About Science Patients News Partnering About Our Purpose Who We Are Careers & Culture Menu Our Purpose Who We Are Careers & Culture Science SORT LNP Platform Pipeline Menu SORT LNP Platform Pipeline Patients Who We Serve Cystic Fibrosis Primary Ciliary Dyskinesia Menu Who We Serve Cystic Fibrosis Primary Ciliary Dyskinesia About Science Patients
- [Fact Sheets](https://recodetx.com/?elementor_library=fact-sheets) - Fact Sheets CORPORATE FACT SHEET CAREERS ONE-PAGER
- [ThinkPCD](https://recodetx.com/?elementor_library=thinkpcd) - Visit ThinkPCD.com If you have experienced symptoms of PCD, such as chronic respiratory infections starting when you were a child, we strongly encourage you to visit ThinkPCD.com. Sign up to receive: Free genetic testing Have a hand in the future of PCD treatment options Receive alerts for relevant research opportunities Access expert, condition-specific educational material
- [Default Kit](https://recodetx.com/?elementor_library=default-kit)
- [Vladimir Kharitonov, Ph.D.](https://recodetx.com/?elementor_library=vladimir-kharitonov-ph-d) - Vladimir Kharitonov, Ph.D. Senior Vice President, CMC and Pharmaceutical Sciences Dr. Kharitonov is a scientist, product development specialist and commercial manufacturing expert with more than 25 years of experience working in biotech/pharma research and development. Throughout his career he also led engineering, technology transfer and commercial manufacturing teams at biotechnology and pharmaceutical companies and at
- [David J. Lockhart, Ph.D.](https://recodetx.com/?elementor_library=david-lockhart-sab) - David J. Lockhart, Ph.D. Scientific Advisory Board Member Dr. Lockhart is an accomplished biotech executive with more than 25 years of experience across all phases of drug discovery, drug development and technology development. He currently serves as a member of ReCode Therapeutics’ Scientific Advisory Board, following his tenure as the company’s President and Chief Scientific
- [Oleg Nodelman](https://recodetx.com/?elementor_library=oleg-nodelman) - Basheer Zada EcoR1 Capital Basheer Zada is a Principal at EcoR1 Capital. Prior to joining EcoR1 in 2018, Mr. Zada was a Senior Associate at Brace Pharma Capital, a life sciences focused venture capital firm. Mr. Zada currently serves as a board member for Actio Biosciences. Mr. Zada holds a Bachelor of Science degree in
- [Max Barker](https://recodetx.com/?elementor_library=max-barker) - Max Barker, J.D. General Counsel Mr. Barker is a legal and financial executive with experience in a broad range of biotechnology transactions, including initial public offerings, mergers and acquisitions, licensing, and other financing and strategic transactions. Prior to joining ReCode Therapeutics in 2020, Mr. Barker served as vice president, legal affairs & corporate development at
- [Shehnaaz Suliman, M.D., M.B.A., M.Phil.](https://recodetx.com/?elementor_library=shehnaaz-suliman) - Shehnaaz Suliman, M.D., M.B.A., M.Phil. President & Chief Executive Officer Dr. Suliman is a physician, drug developer and dealmaker with over 25 years of experience building and transforming small and large biopharmaceutical companies. Prior to becoming CEO of ReCode Therapeutics in January 2022, she served as president and chief operating officer of Alector, a leading
- [Two highlights side by side](https://recodetx.com/?elementor_library=two-highlights-side-by-side) - Strategic Investment from the Cystic Fibrosis Foundation Strategic Investment from the Cystic Fibrosis Foundation Strategic Collaboration Explores Single Vector Gene-Editing Platform Strategic Collaboration Explores Single Vector Gene-Editing Platform
- [Marco Weinberg, Ph.D.](https://recodetx.com/?elementor_library=marco-weinberg-ph-d) - Marco Weinberg, Ph.D. Head of Research Dr. Weinberg has been a leader in industry and in academia for more than 15 years, focusing his research on gene therapy, gene editing and nucleic acid therapies across a wide range of therapeutic targets in rare diseases and infectious disease. He has published more than 70 scientific papers
- [Erica Jefferson](https://recodetx.com/?elementor_library=erica-jefferson) - Erica V. Jefferson Senior Vice President, Corporate Affairs Ms. Jefferson has nearly 20 years of broad communications and external affairs experience leading public health agencies and biopharma companies. Most recently, she served as associate commissioner of external affairs for the U.S. Food and Drug Administration (FDA) where she set agency-wide communications strategy, served as the
- [Teri Keffer](https://recodetx.com/?elementor_library=teri-keffer) - Teri Keffer Senior Vice President, People Ms. Keffer has more than 20 years’ experience through developing talent, building teams, and architecting organizational workflows that catapult biotechnology companies into employers of choice. Prior to ReCode, Ms. Keffer headed global talent acquisition at Ultragenyx Pharmaceutical Inc. While there, she built the recruiting team and provided strategic direction
- [Ariel Kantor, Ph.D.](https://recodetx.com/?elementor_library=ariel-kantor-ph-d) - Ariel Kantor, Ph.D. Senior Vice President, Business and Corporate Development Dr. Kantor is a scientist, entrepreneur, and company builder with over 10 years of experience in the genetic medicines field. He is Senior Vice President and leads Business and Corporate Development at ReCode. Previously, Dr. Kantor served as an entrepreneur in residence at Oxford Science
- [SAB Andrew Bellinger](https://recodetx.com/?elementor_library=sab-andrew-bellinger) - Andrew Bellinger, M.D., Ph.D. Scientific Advisory Board Member Dr. Bellinger brings a deep understanding of gene correction, genetic payload discovery and rare disease drug development experience to ReCode’s SAB. Most recently, he served as chief scientific officer at Verve Therapeutics. Just prior, he co-founded and served as chief scientific officer of Lyndra Therapeutics, where he
- [SAB Katalin Karikó](https://recodetx.com/?elementor_library=sab-katalin-kariko) - Katalin Karikó, Ph.D. Scientific Advisory Board Member Dr. Karikó is a world-renowned biochemist and researcher who was awarded the 2023 Nobel Prize in Medicine alongside Drew Weissman, M.D., Ph.D., for their discoveries that enabled the use of modified mRNA, which was critical for the success of COVID-19 vaccines, and has laid the groundwork for the
- [Exit Interstitial](https://recodetx.com/?elementor_library=exit-interstitial) - External Link You are leaving the ReCode Therapeutics website. ReCode Therapeutics is not responsible for any information or statements you come across on the Internet that are outside of its official website. I acknowledge and choose to proceed.
- [Event Loop Item](https://recodetx.com/?elementor_library=elementor-loop-item-2) - Read More
- [Dean J. Mitchell](https://recodetx.com/?elementor_library=dean-j-mitchell) - Dean J. Mitchell Chairman, Board of Directors Mr. Mitchell currently serves as chairman of the Board of Directors of Praxis Precision Medicines, Inc., an appointment he has held since 2020, and as a board director for Theravance Biopharma, Inc. (since 2014) and Precigen (since 2009). Mr. Mitchell previously served as board chairman of Kinnate Biopharma,
- [Rakhshita Dhar, M.S.](https://recodetx.com/?elementor_library=rakhshita-dhar-m-s) - Rakhshita Dhar, M.S. Leaps by Bayer Rakhshita Dhar is Senior Director of Venture Investments Health at Leaps by Bayer. She joined the team in 2021 and is responsible for search & evaluation and healthcare focused investment for Leaps. She currently sits on the board of Deka Biosciences, Gro Bio, AffiniT therapeutics, Bloom science and Edifice health. Prior
- [John G. Matthews, MBBS, MRCP, Ph.D.](https://recodetx.com/?elementor_library=john-g-matthews-mbbs-mrcp-ph-d) - John G. Matthews, MBBS, MRCP, Ph.D. Chief Medical Officer Dr. Matthews brings over twenty years of proven leadership in clinical trial design and drug development, and extensive patient care experience. He joins ReCode from 23andMe, where he was the senior clinical development lead for rare disease therapeutic strategy. While there, he provided leadership to drug
- [Elementor Single Post #7058](https://recodetx.com/?elementor_library=elementor-single-post-7058)
- [Elementor Single Page #7894](https://recodetx.com/?elementor_library=elementor-single-page-7894) - Events
- [Events_2](https://recodetx.com/?elementor_library=events_2)
- [Events_1](https://recodetx.com/?elementor_library=events_1) - Events
- [Events Archive](https://recodetx.com/?elementor_library=events-archive) - Events
- [Simple Title](https://recodetx.com/?elementor_library=simple-title)
- [Archive Posts](https://recodetx.com/?elementor_library=archive-posts)
- [Ed Hurwitz, J.D., M.B.A.](https://recodetx.com/?elementor_library=ed-hurwitz-j-d-m-b-a) - Ed Hurwitz, J.D., M.B.A. MPM Capital Mr. Hurwitz, an accomplished biotech executive and investor, is a Managing Director at MPM Capital and serves as Chairman of MPM portfolio companies BioIntervene and Rekindle Therapeutics, and on the board of Dyne Therapeutics. Prior to MPM, he was founder and Managing Director of Precision BioVentures, where he founded
- [Alan Colowick, M.D., M.P.H.](https://recodetx.com/?elementor_library=alan-colowick-m-d-m-p-h) - Alan Colowick, M.D., M.P.H. Matrix Capital Management Company Alan Colowick is Senior Managing Director on the Technology-Life Sciences team at Matrix Capital Management Company, LP and its affiliate, AyurMaya Capital Management Company, LP. He currently also serves on the BODs of Acelyrin Inc, Alumis Therapeutics, Solve Therapeutics, Personalis, Inc., AC Immune SA, Harpoon Therapeutics, Inc.,
- [SAB Carrolee Barlow](https://recodetx.com/?elementor_library=sab-carrolee-barlow) - Carrolee Barlow, M.D., Ph.D. Scientific Advisory Board Member Dr. Barlow was most recently the chief medical officer of ESCAPE Bio, Inc. Prior to joining ESCAPE Bio, she served as chief executive officer of the Parkinson’s Institute and Clinical Center. Dr. Barlow was also formerly acting chief medical officer at Amicus Therapeutics and was a co-founder,
- [SAB Eric Olson](https://recodetx.com/?elementor_library=sab-eric-olson) - Eric Olson, Ph.D. Scientific Advisory Board Member Dr. Olson is the founding chair of the department of molecular biology at the University of Texas Southwestern Medical Center. He also directs the Hamon Center for Regenerative Science and Medicine and the Wellstone Center for Muscular Dystrophy Research. He holds the Robert A. Welch Distinguished Chair, the
- [SAB Rafael Amado](https://recodetx.com/?elementor_library=sab-rafael-amado) - Rafael Amado, M.D. Scientific Advisory Board Member Dr. Amado serves as president, head of global oncology research and development at Zai Labs. He most recently served as executive vice president of research and development at Allogene Therapeutics, Inc., and previously, president of research and development at Adaptimmune Therapeutics PLC, after serving as its chief medical officer. He has held
- [SAB Daniel J. Siegwart](https://recodetx.com/?elementor_library=sab-daniel-j-siegwart-2) - Daniel J. Siegwart, Ph.D. Chair of the Scientific Advisory Board Dr. Siegwart is the W. Ray Wallace Distinguished Chair in Molecular Oncology Research and associate professor in the Department of Biochemistry at the University of Texas Southwestern Medical Center and is a co-founder of ReCode Therapeutics. Dr. Siegwart has been a pioneer in the design
- [SAB Elliott Sigal](https://recodetx.com/?elementor_library=sab-elliott-sigal) - Elliott Sigal, M.D., Ph.D. Scientific Advisor Dr. Sigal currently serves as co-chair of the scientific advisory board for Amgen, Inc. and as a senior advisor to New Enterprise Associates, Inc. He is a member of the Board of Directors for Adaptimmune Therapeutics, Vir Biotechnology, Surface Oncology, Tessera Therapeutics and Affinia Therapeutics. He is a former
- [SAB Justin Hanes v2](https://recodetx.com/?elementor_library=sab-justin-hanes-v2) - Justin Hanes, Ph.D. Scientific Advisory Board Member Dr. Hanes is the Lewis J. Ort professor of ophthalmology at the Wilmer Eye Institute at Johns Hopkins University, with secondary appointments in chemical & biomolecular engineering, environmental health sciences, neurosurgery and oncology. A globally recognized leader of research at the interface of nanotechnology and medicine, Dr. Hanes
- [BOD Trisha Millican](https://recodetx.com/?elementor_library=bod-trisha-millican) - Trisha MillicanReCode Therapeutics Ms. Millican has over 20 years of experience in the life science industry including debt and equity financings, mergers and acquisitions, company formation, licensing transactions, co-development/promotional arrangements, and commercial product launches. Currently, Ms. Millican is a strategic advisor to various life science companies and serves on the board of Life Science Cares,
- [Values Carousel Item](https://recodetx.com/?elementor_library=elementor-loop-item)
- [Header](https://recodetx.com/?elementor_library=header) - Pipeline
- [CFF and AskBio](https://recodetx.com/?elementor_library=cff-and-askbio) - Strategic Investment from the Cystic Fibrosis Foundation ReCode receives strategic investment from the Cystic Fibrosis Foundation of up to $15 million to support preclinical studies needed for an Investigational New Drug (IND) application and early clinical development of ReCode’s CFTR mRNA therapy for cystic fibrosis. Learn more Strategic Collaboration Explores Single Vector Gene-Editing Platform ReCode
- [Values Carousel](https://recodetx.com/?elementor_library=values-carousel)
- [Curved Divider Widget](https://recodetx.com/?elementor_library=curved-divider-widget)
- [Curved Divider (Upright)](https://recodetx.com/?elementor_library=curved-divider-upright)
- [Light Gradient Divider (Sm)](https://recodetx.com/?elementor_library=light-gradient-divider-sm)
- [Featured News](https://recodetx.com/?elementor_library=featured-news) - Press Releases Media Contacts ReCode Therapeutics Erica Jefferson ejefferson@recodetx.com The Grace Communication Group Tara Cooper tara@gracegroup.us media@recodetx.com Investor Contact Stern IR AnneMarie Fields annemarie.fields@sternir.com ir@recodetx.com
- [Gradient Divider](https://recodetx.com/?elementor_library=gradient-divider)
- [Top Bar_Two Column Text](https://recodetx.com/?elementor_library=top-bar_two-column-text) - Powering the Next Wave of Precision Genetic Medicines — Together Our goal is to maximize the potential of our SORT LNP delivery technology even beyond those rare diseases in our pipeline so that more patients may realize the full benefit of genetic medicines. We believe in winning together and importantly, winning in our shared mission to
- [Gradient BG](https://recodetx.com/?elementor_library=gradient-bg) - Posters + Publications
- [Central Text Box Over Image](https://recodetx.com/?elementor_library=central-text-box-over-image) - “We can enhance the potency of any genetic cargo by packaging it using our SORT LNP platform and delivering it directly to the organs and cells impacted by disease. This creates vast opportunities to address a wide range of medical needs not possible with current technologies.” Shehnaaz Suliman, M.D., M.B.A., M.Phil.Chief Executive Officer
- [Button](https://recodetx.com/?elementor_library=button) - Learn more
- [Hero_ImgCollage](https://recodetx.com/?elementor_library=hero_imgcollage) - Powering the future of genetic medicines through precision delivery
- [Custom Post](https://recodetx.com/?elementor_library=custom-post) - Read More
- [News Archive](https://recodetx.com/?elementor_library=news-archive)
- [Archive with Pagination](https://recodetx.com/?elementor_library=archive-with-pagination)
- [Archive](https://recodetx.com/?elementor_library=archive)
- [Event](https://recodetx.com/?elementor_library=event) - | Read More
- [Elementor Section #7096](https://recodetx.com/?elementor_library=elementor-section)
- [BOD David Lockhart](https://recodetx.com/?elementor_library=bod-david-lockhart) - David J. Lockhart, Ph.D. ReCode Therapeutics
- [RA Session II](https://recodetx.com/?elementor_library=ra-session-ii-2) - RA Session II, M.B.A. Taysha Gene Therapies
- [Peter Thompson, M.D.](https://recodetx.com/?elementor_library=peter-thompson-m-d) - Peter Thompson, M.D. OrbiMed Advisors Dr. Thompson is a partner on the private equity team at OrbiMed Advisors LLC. With over 25 years of industry experience, he has held executive positions at Becton-Dickinson and Chiron, co-founded and was CEO of Trubion Pharmaceuticals, co-founded Corvus Pharmaceuticals, Cleave Biosciences, Silverback Therapeutics and serves as a director on
- [Rana Al-Hallaq, Ph.D.](https://recodetx.com/?elementor_library=rana-al-hallaq-ph-d) - Rana Al-Hallaq, Ph.D. Pfizer Ventures Dr. Al-Hallaq is Executive Director and Partner at Pfizer Ventures. Dr. Al-Hallaq leverages her preclinical, clinical, and business development experience to assess, invest in, and manage equity investments for Pfizer Ventures. She currently has responsibility for Pfizer’s investments in Mitokinin, Inc. (San Francisco, CA), Autifony Therapeutics Ltd. (Stevenage, UK), Blade
- [Helen Kim, M.B.A.](https://recodetx.com/?elementor_library=helen-kim-m-b-a) - Helen Kim, M.B.A. Vida Ventures Ms. Kim is a Managing Director of Vida Ventures, a life sciences focused venture capital firm. Most recently, Ms. Kim was a Partner at The Column Group. Previously, she served as Executive Vice President of Business Development at Kite Pharma, Inc., where she led business and corporate development initiatives including
- [BOD Shehnaaz Suliman](https://recodetx.com/?elementor_library=bod-shehnaaz-suliman) - Shehnaaz Suliman, M.D., M.B.A., M.Phil. ReCode Therapeutics Dr. Suliman is a physician, drug developer and dealmaker with over 25 years of experience building and transforming small and large biopharmaceutical companies. Prior to becoming CEO of ReCode Therapeutics in January 2022, she served as president and chief operating officer of Alector, a leading immuno-neurology and immuno-oncology
- [Team](https://recodetx.com/?elementor_library=team) - Leadership Shehnaaz Suliman, M.D., MBA, M.Phil. Chief Executive Officer David J. Lockhart, Ph.D. President & Chief Scientific Officer Angèle Maki, Ph.D. Senior Vice President, Business Development Brandon A. Wustman, Ph.D. Senior Vice President, Business Development Nick P. France, M.D. Senior Vice President, Clinical Development Vladimir G. Kharitonov, Ph.D. Senior Vice President, CMC April Board of
- [Pipeline Intro](https://recodetx.com/?elementor_library=pipeline-intro) - Cystic Fibrosis (CF) ReCode’s CFTR mRNA is an investigational therapy for CF that focuses specifically on the 10%-13% of CF patients who have nonsense mutations and do not respond to currently approved CFTR modulators Primary Ciliary Dyskinesia (PCD) ReCode is developing DNAI1 mRNA for the treatment of PCD caused by mutations in DNAI1, an essential
- [Collage of three right](https://recodetx.com/?elementor_library=collage-of-three-right) - The Why Behind our Work We imagine a world where people living with rare, genetic diseases can fully benefit from the promise of genetic medicines. We are realizing this promise with novel mRNA-based and gene correction therapeutics that address the underlying cause of diseases that result from mutations and genetic defects, including cystic fibrosis (CF),

## Events

- [Morgan Stanley Healthcare Conference](https://recodetx.com/events/morgan-stanley-healthcare-conference/)
- [RNA Leaders USA Congress](https://informaconnect.com/rna-leaders-usa/#new_tab)
- [47th European Cystic Fibrosis Conference](https://www.pipersandler.com/conferences-and-events#new_tab)
- [Virtual Piper Sandler Lung Day Post-ATS](https://www.pipersandler.com/conferences-and-events#new_tab)
- [American Thoracic Society: Respiratory Innovation Summit](https://conference.thoracic.org/program/ris/#new_tab)
- [TIDES USA 2024](https://informaconnect.com/tides/?utm_source=google&utm_medium=cpc&utm_campaign=3081_-_S_-_TIDES_USA_-_2024_-_Delprom_-_B_-_DCN&gad_source=1&gclid=CjwKCAjwrcKxBhBMEiwAIVF8rL39WEDNKeVeJ925P9LXBvpJKy5czwKXv0qQW4RbOkYCYU-LuvYOzhoCnHUQAvD_BwE#new_tab)
- [Capital One Biotech - Life Sciences Disruptors](https://recodetx.com/events/capital-one-biotech-life-sciences-disruptors/)
- [ASGCT Annual Meeting](https://annualmeeting.asgct.org/#new_tab)
- [Wells Fargo Virtual Private Biotech Symposium](https://recodetx.com/events/wells-fargo-virtual-private-biotech-symposium/)
- [LNP Formulation & Process Development Summit](https://lnp-formulation-process-development-pharma.com/#new_tab)
- [Evercore ISI 2024 Emerging Biotech Conference](https://www.evercore.com/our-business-and-capabilities/equities/corporate-access-conferences/#new_tab)
- [William Blair Private Company Focus Conference](https://www.williamblair.com/Investment-Banking/Private-Equity#new_tab)
- [J.P. Morgan Healthcare Conference](https://www.jpmorgan.com/about-us/events-conferences/health-care-conference#new_tab)
- [Jefferies CNS & Neuro Summit](https://www.jefferies.com/OurFirm/ConferenceList/Investment-Conferences/159#new_tab)
- [15th Stifel Healthcare Conference](https://recodetx.com/events/15th-stifel-healthcare-conference-nyc/)
- [Jefferies London Healthcare Conference](https://www.jefferies.com/OurFirm/ConferenceList/Investment-Conferences/159#new_tab)
- [BIO Europe Conference](https://informaconnect.com/bioeurope/#new_tab)
- [North American Cystic Fibrosis Conference (NACFC)](https://www.nacfconference.org/#new_tab)
- [Piper Sandler 35th Annual Healthcare Conference](https://www.pipersandler.com/conferences-and-events#new_tab)
- [Needham Biotech Private Company Virtual 1x1 Forum](https://www.needhamco.com/conferences/3rd-needham-private-biotech-1x1-forum/#new_tab)
- [Meeting on the Mesa](https://meetingonthemesa.com/agenda/#new_tab)
- [Partnership Opportunities in Drug Development Meeting](https://theconferenceforum.org/conferences/partners-in-drug-delivery/overview/#new_tab)
- [Biotech Investors & CEO Sisterhood Event](https://recodetx.com/events/biotech-investors-ceo-sisterhood-event/)
- [Chardan 7th Annual Genetic Medicines](https://www.chardan.com/events/ZJs-YBAAACYAKD_W)
- [Jefferies Cell & Genetic Medicine Summit](https://recodetx.com/events/jefferies-cell-genetic-medicine-summit/)
- [BMO BioPharma Spotlight Series: Latest Advances in Genome/Epigenome Editing](https://recodetx.com/events/bmo-biopharma-spotlight-series-latest-advances-in-genome-epigenome-editing/)
- [Rett Syndrome Genetic Medicines Summit](https://recodetx.com/events/rett-syndrome-genetic-medicines-summit/)
- [Morgan Stanley Annual Global Healthcare Conference](https://recodetx.com/events/morgan-stanley-annual-global-healthcare-conference/)
- [Inaugural Gene Therapy Potency Assay Summit](https://genetherapy-potency-assay.com/#new_tab)
- [2nd Next Gen Lipid-Based Nanoparticles Delivery Summit](https://lipid-nanoparticle-delivery-summit.com/#new_tab)
- [9th Meeting on Genome Engineering: CRISPR Frontiers](https://meetings.cshl.edu/meetings.aspx?meet=crispr&year=23#new_tab)
- [15th Annual Bioprocessing Summit](https://www.bioprocessingsummit.com/#new_tab)
- [3rd mRNA-based Therapeutics Summit](https://mrnabased-therapeutics.com/#new_tab)
- [6th World Congress on Nanomedicine and Drug Delivery](https://scholarsconferences.com/drugdelivery-nanomedicine/#new_tab)
- [BIO International Convention](https://www.bio.org/events/bio-international-convention/registration-information?utm_medium=paid-search&utm_source=google&utm_campaign=international-convention-2023-search&utm_term=bio2023&gclid=CjwKCAjw0ZiiBhBKEiwA4PT9z_LnHAIQOw_WT3pp0NJkkJnP-5xBLi-FHiga6oY19cNR8USed2KPTRoCxM4QAvD_BwE#new_tab)
- [2023 Jefferies Healthcare Conference](https://www.jefferies.com/OurFirm/ConferenceList/Investment-Conferences/159#new_tab)
- [European Cystic Fibrosis Conference](https://www.ecfs.eu/vienna2023#new_tab)
- [Cystic Fibrosis Foundation Great Strides Walk](https://fightcf.cff.org/site/TR/GreatStrides/111_San_Diego_San_Diego?pg=entry&fr_id=9717#new_tab)
- [American Thoracic Society](https://conference.thoracic.org/#new_tab)
- [Cystic Fibrosis Foundation: Great Strides Walk](https://fightcf.cff.org/site/TR/GreatStrides/98_Northern_California_San_Francisco?pg=entry&fr_id=9493#new_tab)
- [Locust Walk RNA Innovation Conference](https://wsw.com/webcast/locust2/reco/2036620#new_tab)
- [TIDES USA](https://informaconnect.com/tides/agenda/1/#new_tab)
- [LNP Formulation & Process Development Summit](https://lnp-formulation-process-development-pharma.com/#new_tab)
- [Guggenheim Genomic Medicines & Rare Disease Day](https://recodetx.com/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days/)
- [Keystone Genome Precision Engineering](https://www.emedevents.com/c/medical-conferences-2023/precision-genome-engineering-2023#new_tab) - Where: Whistler, British Columbia, Canada When: March 21, 2023 Learn More: https://www.emedevents.com/c/medical-conferences-2023/precision-genome-engineering-2023
- [Cowen 43rd Annual Healthcare Conference](https://www.cowen.com/conferences-and-events/cowens-43rd-annual-health-care-conference/#new_tab) - Where: Boston, Massachusetts When: March 6–8, 2023 Learn More: https://www.cowen.com/conferences-and-events/cowens-43rd-annual-health-care-conference/
- [RNA Leaders Congress](https://www.lsxleaders.com/rna-leaders-world-congress#new_tab) - Where: Congress Center Basel, Switzerland When: March 16, 2023 Learn More: lsxleaders.com/rna-leaders-world-congress
- [BIO Europe Spring](https://informaconnect.com/bioeurope-spring/agenda/5/#new_tab) - Where: Basel, Switzerland When: March 20-22, 2023 Learn More: https://informaconnect.com/bioeurope-spring/agenda/4/
- [BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines](https://capitalmarkets.bmo.com/en/about-us/conferences/) - Where: Toronto, Canada When: March 28, 2023 Learn More: https://capitalmarkets.bmo.com/en/about-us/conferences/
- [ECFS Basic Science Conference](https://www.ecfs.eu/conference/basic-science-conference-croatia-2023#new_tab) - Where: Dubrovnik, Croatia When: March 29 - April 1, 2023 Learn More: https://www.ecfs.eu/conference/basic-science-conference-croatia-2023

## Values

- [Generate Audacious Science.](https://recodetx.com/values/generate-audacious-science/) - With cutting edge science, we innovate without bounds.
- [Think It. Own It. Do It.](https://recodetx.com/values/think-it-own-it-do-it/) - We have the autonomy to be bold and drive positive change.
- [Act with Urgency.](https://recodetx.com/values/act-with-urgency/) - We move expediently and efficiently, with thoughtful and considerate actions.
- [Be Curious. Be Kind. Be Yourself.](https://recodetx.com/values/be-curious-be-kind-be-yourself/) - We embrace a culture of exploration and belonging.
- [Solve Together.](https://recodetx.com/values/solve-together/) - We collaborate with shared trust and camaraderie.
- [Patients First.](https://recodetx.com/values/patients-first/) - We truly care and strive to deliver impactful medicines to patients in need.

## Categories

- [Press Releases](https://recodetx.com/category/press-releases/)
- [Presentations](https://recodetx.com/category/presentations/)
- [Publications](https://recodetx.com/category/publications/)
- [Careers](https://recodetx.com/category/careers/)
- [Featured](https://recodetx.com/category/featured/)

## Tags

- [American Thoracic Society (ATS)](https://recodetx.com/tag/american-thoracic-society-ats/)
- [Cilia2022](https://recodetx.com/tag/cilia2022/)
- [J.P. Morgan](https://recodetx.com/tag/j-p-morgan/)
- [Gordon Research Conferences](https://recodetx.com/tag/gordon-research-conferences/)
- [Featured](https://recodetx.com/tag/featured/)
- [North American Cystic Fibrosis Conference](https://recodetx.com/tag/north-american-cystic-fibrosis-conference/)
- [NACFC](https://recodetx.com/tag/nacfc/)
- [Journal of Cystic Fibrosis](https://recodetx.com/tag/journal-of-cystic-fibrosis/)
- [Science](https://recodetx.com/tag/science/)
- [PNAS](https://recodetx.com/tag/pnas/)